AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Darren A. E. Cross¹, Susan E. Ashton¹, Serban Ghiorghiu¹, Cath Eberlein¹, Caroline A. Nebhan³, Paula J. Spitzler³, Jonathon P. Orme², M. Raymond V. Finlay¹, Richard A. Ward¹, Martine J. Mellor¹, Gareth Hughes¹, Amar Rahi¹, Vivien N. Jacobs¹, Monica Red Brewer³, Eiki Ichihara³, Jing Sun³, Hailing Jin³, Peter Ballard¹, Katherine Al-Kadhimi¹, Rachel Rowlinson¹, Teresa Klinowska¹, Graham H. P. Richmond¹, Mireille Cantarini¹, Dong-Wan Kim⁴, Malcolm R. Ranson⁵, William Pao³

AstraZeneca Oncology Innovative Medicines¹ and Discovery Sciences², Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, United Kingdom; ³Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232 USA; ⁴Seoul National University Hospital, Seoul, Republic of Korea, ⁵University of Manchester, Christie Hospital, Manchester, M20 4BX, United Kingdom

Running Title

Novel mutant-selective EGFR inhibitor overcomes drug resistance

Key Words

EGFR mutant lung cancer, AZD9291, EGFR tyrosine kinase inhibitor
Abbreviations

EGF; epidermal growth factor
EGFR; EGF receptor
EGFRm+; EGFR mutant NSCLC tumors
EMT; epithelial mesenchymal transition
IGF-1R; insulin-like growth factor receptor
IR; insulin receptor
NSCLC; Non small cell lung cancer
TKI; tyrosine kinase inhibitor

Notes

Financial Support

This work was supported by AstraZeneca. Some of this work was supported in part by grants from the V Foundation (to W. Pao) and the NCI (R01-CA121210, P01-CA129243, and U54-CA143798 to W. Pao). W. Pao received additional support from Vanderbilt’s Specialized Program of Research Excellence in Lung Cancer grant (CA90949) and the VICC Cancer Center Core grant (P30-CA68485). Imaging support to W. Pao was provided by NCI P30 CA68485.

To whom correspondence should be addressed:
Darren Cross, PhD
AstraZeneca
Alderley Park
Macclesfield
UK
SK10 4TG
Office: +44 1625 515649
Disclosure of Potential Conflicts of Interest

A patent relating to EGFR T790M mutation testing was licensed on behalf of William Pao and others by Memorial Sloan-Kettering Cancer Center to MolecularMD. Malcolm Ranson and William Pao received research funding from AstraZeneca. D.A.E. Cross, S.E. Ashton, S. Ghiorghiu, C. Eberlein, J.P. Orme, M.R.V. Finlay, R.A. Ward, M.J. Mellor, G. Hughes, A. Rahi, V.N. Jacobs, K. Al-Kadhimi, T. Klinowska, G.H.P. Richmond and M. Cantarini are employees of AstraZeneca.
Abstract

First generation EGF receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant clinical benefit in patients with advanced EGFR mutant (EGFRm+) non-small cell lung cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resistance mutation. AZD9291 is a novel oral, potent and selective third generation irreversible inhibitor of both EGFRm+ sensitizing and T790M resistance mutants that spares wild-type EGFR. This mono-anilino-pyrimidine compound is structurally distinct from other third generation EGFR TKIs and offers a pharmacologically differentiated profile from earlier generation EGFR TKIs. Pre-clinically, the drug potently inhibits signaling pathways and cellular growth in both EGFRm+ and EGFRm+/T790M mutant cell lines in vitro, with lower activity against wild-type EGFR lines, translating into profound and sustained tumor regression in EGFR mutant tumor xenograft and transgenic models. The treatment of two patients with advanced EGFRm T790M+ NSCLC is described as proof of principle.

SIGNIFICANCE

We report development of a novel structurally distinct third generation EGFR TKI, AZD9291, that irreversibly and selectively targets both sensitizing and resistant-T790M mutant EGFR whilst harboring less activity towards wild-type EGFR. AZD9291 is showing promising responses in a Phase I trial even at the first dose level, with first published clinical proof of principle validation being presented.
Introduction

Gefitinib (1) and erlotinib (2) are reversible small molecule ATP analogues originally designed to inhibit the tyrosine kinase (TK) activity of wild-type epidermal growth factor receptor (EGFR). During their clinical development, these first-generation TK inhibitors (TKIs) were serendipitously found to be most effective in advanced non-small cell lung cancer (NSCLC) patients whose tumors harbor recurrent somatic activating mutations occurring in the exons encoding the kinase domain of EGFR, i.e. small multi-nucleotide in-frame deletions in exon 19 (ex19del) and a point mutation in exon 21 leading to substitution of leucine for arginine at position 858 (L858R) (3-5). Tumors with these activating mutations (EGFRm+) account for approximately 10-15% and 40% of NSCLC in Western and Asian populations respectively (6). Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11). Furthermore, these first generation TKIs are associated with side effects that include skin rash and diarrhea that are due to the inhibition of wild-type EGFR in skin and gastrointestinal organs (12).

Preclinical modeling and analysis of tumor tissue obtained from patients after the development of disease progression has led to the identification of a number of mechanisms that mediate EGFR TKI resistance. Such genetic and other signaling aberrations that drive resistance mechanisms include HER2 amplification (13), MET amplification (14, 15), PIK3CA mutation (16), BRAF mutation (17), NF1 loss (18) and potentially FGFR signaling (19). In addition, resistant tumors have also been reported to show histologic changes such as small cell lung cancer (SCLC) transformation or
epithelial mesenchymal transition (EMT) (16). However, it is now well established that acquisition of a second mutation in EGFR, resulting in substitution of threonine at the “gatekeeper” amino acid 790 to methionine (T790M) is the most common resistance mechanism and is detected in tumor cells from more than 50% of patients after disease progression (20, 21). The T790M mutation is believed to render the receptor refractory to inhibition by these reversible EGFR TKIs through exerting effects on both steric hindrance (22) and increased ATP affinity (23).

Current targeted therapeutic strategies for patients with acquired resistance are limited. Second-generation irreversible EGFR TKIs such as afatinib (24) and dacomitinib (25) are effective in untreated EGFR mutant lung cancer (26, 27). However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30). Furthermore, these inhibitors can drive resistance through acquisition of T790M in vitro (31) and in patients (32), providing supportive evidence that they have low potency against T790M. One regimen that showed potential activity is afatinib plus the anti-EGFR antibody, cetuximab, which induced a 32% unconfirmed response rate in a phase IB trial for patients with EGFRm+ lung cancer and acquired resistance to erlotinib (33). However, this combination has substantial skin toxicity with 18% of patients reporting CTCAE grade 3 or higher rash (33).

Therefore, there remains a significant unmet need for an EGFR TKI agent that can more effectively target T790M tumors while sparing the activity of wild-type EGFR.
This has led to the development of “third generation” EGFR TKIs that are designed to target T790M and EGFR TKI-sensitizing mutations more selectively than wild-type EGFR. WZ4002 was the first such agent to be published (34), although it has not progressed to clinical trials. A second agent closely related to the WZ4002 series, CO-1686, has been recently reported (35), and is currently in early Phase II clinical trials. HM61713 is another “third generation” agent that is currently in early Phase I trials.

Here, we describe identification, characterization, and early clinical development of AZD9291, a novel, irreversible, EGFR TKI with selectivity against mutant versus wild-type forms of EGFR. AZD9291 is a mono-anilino-pyrimidine compound that is structurally and pharmacologically distinct from all other TKIs including CO-1686 and WZ4002.

Results

AZD9291 is a mutant-selective, irreversible inhibitor of EGFR kinase activity

AstraZeneca developed a novel series of irreversible, small-molecule inhibitors to target the sensitizing and T790M resistant mutant forms of the EGFR tyrosine kinase with selectivity over the wild-type form of the receptor. These compounds bind to the EGFR kinase irreversibly by targeting the cysteine-797 residue in the ATP binding site via covalent bond formation (36), as depicted in the modeling structure for AZD9291 (Fig. 1A). Further work on this chemotype allowed additional structure activity relationships (SAR) to be discerned that enabled target potency to be increased without driving increased lipophilicity, thus maintaining favorable drug-like properties. Continued medicinal chemistry efforts achieved further improvements including
increased kinase selectivity, ultimately arriving at the mono-anilino-pyrimidine AZD9291 (Fig. 1B). Mass spectrometry of chymotrypsin digests confirmed that AZD9291 can covalently modify recombinant EGFR (L858R/T790M) at the target cysteine 797 amino acid (Supplementary Fig. S1 A&B).

AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35). Whilst the former two compounds share a number of common structural features (e.g. positioning of the electrophilic functionality that undergoes reaction with a conserved cysteine residue present in EGFR (Cys 797), heteroatom-linked pyrimidine 4-substituents, and presence of a pyrimidine 5-substituent), AZD9291 is architecturally unique. Amongst other differences, the electrophilic functionality resides on the pyrimidine C-2 substituent ring, the pyrimidine 4-substituent is C-linked and heterocyclic, and the pyrimidine 5-position is devoid of substitution.

In EGFR recombinant enzyme assays (Millipore), AZD9291 showed an apparent IC$_{50}$ of 12 nM against L858R and 1 nM against L858R/T790M; these are called apparent since the amount of active enzyme changes over time and thus IC$_{50}$ is time-dependent for irreversible agents. The drug exhibited nearly 200 times greater potency against L858R/T790M than wild-type EGFR (Supplementary Table S1A), consistent with the design goal of a mutant EGFR selective agent in comparison to early generation TKIs. Subsequent murine in vivo studies revealed that AZD9291 was metabolized to produce at least two circulating metabolite species, AZ5104 and AZ7550. In biochemical assays, AZ7550 had a comparable potency and selectivity profile to the parent (Supplementary Table S1A). In contrast, although AZ5104
exhibited the same overall profile, it was more potent against mutant and wild-type
EGFR forms, thus demonstrating a smaller selectivity margin compared to parent
(Supplementary Table S1A).

To explore a broader kinome selectivity profile, we tested AZD9291 and
metabolites at 1 μM across approximately 280 other kinases available on a commercial
biochemical kinome panel (Millipore). AZD9291 showed minimal off-target kinase
activity, with only a limited number of additional kinases showing greater than 60%
inhibition at 1 μM and moderate IC₅₀ potencies such as ErbB2/4, ACK1, ALK, BLK,
BRK, MLK1 and MNK2 (Supplementary Table S1B). The active metabolites displayed
a similar secondary target profile as parent (Supplementary Table S1B). Given that
AZD9291 makes a covalent bond with Cys797 in EGFR as described, we were
specifically interested to explore potency in other kinases that have a cysteine residue
in the analogous kinase domain position. Of the nine other kinases present within the
human kinome with the analogous Cys797 to EGFR, AZD9291 showed significant
activity only in a biochemical assay against ErbB2, ErbB4 and BLK (Supplementary
Table S1B), supporting the overall high degree of selectivity that AZD9291 confers.

Like the T790M double-mutant EGFR receptor, the insulin-like growth factor
receptor (IGF-1R) and insulin receptor (IR) also have a methionine gatekeeper in their
kinase domains. We considered it important to develop selectivity against these
kinases to minimize potential dose limiting toxicities related to hyperglycaemia. Using a
commercially available cellular IGF-1R phosphorylation assay as a surrogate, AZD9291
and the metabolite AZ5104 did not exhibit significant activity towards this receptor family
(Supplementary Table S1C). Moreover, a single oral dose of 200 mg/kg of AZD9291
in rats did not cause a significant change in blood glucose or insulin levels over a 24 hour period, consistent with lack of IGF-1R activity (data not shown).

Finally, we evaluated cellular potency against HER2 (ErbB2), using three different cellular approaches: surrogate kinase assays involving expression of wild-type HER2 in HEK293 cells (Supplementary Fig. S2A), PC-9 cells (ex19del) engineered to overexpress HER2 (Supplementary Fig. S2B; (13) and biochemical reconstitution studies in HEK293 cells involving intracellular domain constructs encoding L858R/T790M, wild-type EGFR, or wild-type HER2 (Supplementary Fig. S2C; (37). Consistently, treatment of cells with AZD9291 inhibited phosphorylation of HER2 at moderate potency levels. However, consistent with its greater wild-type EGFR potency, the AZ5104 metabolite showed more potency than AZD9291 against phospho-HER2 (Supplementary Fig. S2A-C).

AZD9291 potently and selectively targets mutant EGFR cell lines in vitro

We compared AZD9291 with other early generation EGFR TKIs in EGFR phosphorylation and cell death (Sytox) assays using a number of tumor cell lines harboring either wild-type or different forms of mutant EGFR. Compared with other EGFR inhibitors of both first (gefitinib and erlotinib) and second generation (afatinib and dacomitinib), AZD9291 demonstrated a unique third generation TKI profile. AZD9291 showed similar potency to early generation TKIs in inhibiting EGFR phosphorylation in EGFR cells harboring sensitising EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del) (Fig. 2A), with mean IC50 values ranging from 13 to 54 nM for AZD9291. AZD9291 also potently inhibited phosphorylation of EGFR in T790M...
mutant cell lines (H1975 (L858R/T790M), PC-9VanR (ex19del/T790M)) (Fig. 2A), with mean IC$_{50}$ potency less than 15 nM. First generation reversible TKIs were ineffective at inhibiting phosphorylation of T790M EGFR (Fig. 2A). The second generation irreversible TKIs, afatinib and dacomitinib, showed activity against T790M EGFR in vitro, although this activity is may not be achievable at exposures that can be reached in the clinic. AZD9291 was less potent at inhibiting phosphorylation of EGFR in wild-type cell lines (A431, LOVO, NCI-H2073), with mean IC$_{50}$ range of 480 to 1865 nM (Fig. 2A). This is in clear contrast to the early generation TKIs which all potently inhibited EGFR phosphorylation in wild-type lines with similar potency to sensitizing-mutant EGFR (Fig. 2A). Similar results were found when phosphorylation of EGFR and downstream signaling was determined by immunoblot analysis of lysates from PC-9, H1975, LOVO, H1650 and H3255 lines (Fig. 2B). Consistently, results showed that AZD9291 more potently inhibited phospho-EGFR and downstream signaling substrates (pAKT, pERK) in cells with mutant EGFR compared with wild-type (Fig. 2B), although H1650 cells retained higher phospho-AKT levels due to loss of PTEN (38).

As previously described, AZD9291 has active circulating metabolites, so we also profiled their activity against EGFR. Consistent with presented biochemical data, AZ7550 exhibited very similar potency and profile to AZD9291 against mutant and wild-type cell lines tested (Supplementary Table S1D), whilst AZ5104 harbored somewhat greater potency against ex19del (2 nM in PC-9), T790M (2 nM in H1975) and wild-type EGFR (33 nM in LOVO) cell lines. Therefore, AZ5104 exhibited a reduced selectivity margin against wild-type EGFR when compared to AZD9291. However, taken together, this mechanistic data confirmed the third generation TKI properties of AZD9291.
compared to earlier generation agents: equivalent activity against sensitizing mutant EGFR, superior activity towards T790M and increased selectivity margin against wild-type EGFR.

We then explored how the pharmacological activity against mutant and wild-type EGFR signaling translated into cell proliferation effects using a Sytox live/dead cell phenotype endpoint. In line with the phosphorylation data, AZD9291 showed high levels of phenotype potency in both sensitizing-mutant (mean IC$_{50}$ of 8 nM in PC-9) and T790M (mean IC$_{50}$ of 11 and 40 nM in H1975 and PC-9VanR respectively) EGFR cell lines, whilst having much less activity towards wild-type EGFR (mean IC$_{50}$ of 650 and 461 nM in Calu3 and H2073 respectively) (Fig. 3A). Again, this contrasted to second generation TKIs, afatinib and dacomitinib, which showed much less activity against T790M lines and were associated with much greater potency towards wild-type EGFR (Fig. 3A). To confirm these results, we determined the efficacy of AZD9291 in an independent laboratory against a panel of isogenic pairs of drug-sensitive/resistant EGFR mutant lung cancer cell lines (31, 39). Parental EGFRm+ lines (PC-9, H3255, HCC827, HCC4006, 11-18) were sensitive to AZD9291 as well as erlotinib, afatinib, and AZD8931 (a reversible equipotent inhibitor of EGFR, HER2 and HER3 signalling (40)) (Fig. 3B). However, only AZD9291 displayed low nanomolar activity against the lines harboring EGFR T790M (H1975, HCC827/ER1, PC-9/BRc1 and H3255/XLR) (Fig. 3B). Interestingly, AZD9291 was not effective against lines harboring non-T790M resistance such as 11-18/ER (NRAS), HCC827/ER2 (MET amplification), and HCC4006/ER (EMT) (17) (Fig. 3B). In a separate large cell panel proliferation profiling study, AZD9291 was also poorly active in vitro (IC$_{50}$ ~1 μM) against both NSCLC NCI-H820 and EBC-1 cell
lines that harbor MET amplification and mutant EGFR (data not shown). Consistent with phospho-EGFR data, the metabolite AZ5104 again demonstrated much greater potency across cell lines in a phenotypic assay, whereas AZ7550 was broadly similar, with the same overall profile maintained (Supplementary Table S1E).

Due to their low activity against T790M EGFR, it has been suggested that treatment with early generation TKIs can induce the growth selection of tumor cells harboring EGFRm+/T790M leading to TKI resistant populations both pre-clinically and clinically (31). We therefore hypothesized that such resistance would not occur upon treatment with AZD9291, given its superior potency against T790M. Indeed, whilst chronic treatment with gefitinib or afatinib commonly caused acquired resistance in PC-9 cells in vitro through gain of T790M, acquired resistance to AZD9291 through T790M was not observed (Fig. 3C). Studies are ongoing to characterize the T790M independent mechanisms of acquired resistance to AZD9291 (Eberlein et al., manuscript in preparation).

Activity of AZD9291 against rare EGFR and HER2 mutants in vitro

In addition to activity against the common activating/sensitizing EGFR mutants, we assessed the potency of AZD9291 against other rarer EGFR mutants associated with sensitivity or resistance to first-generation EGFR TKIs (Supplementary Fig. S3). 293 cells were transfected with cDNAs encoding EGFR G719S, L861Q, an exon 20 insertion (H773-V774HVdup), exon 19 insertion (I744-K745insKIPVAI) or an EGFR variant III (EGFRvIII; found in brain glioblastomas (41)), and treated with increasing concentrations of either erlotinib, afatinib, AZD9291, the metabolite AZ5104, or
AZD8931 for 6 hours. Immunoblotting was performed on corresponding lysates using antibodies against phospho-EGFR (Y1173) and total EGFR. All EGFR TKIs were effective against EGFR L861Q (consistent with kinase profiling data (Table 1)), G719S, and the exon 19 insertion, although AZD9291 was somewhat less potent compared with the AZ5104 metabolite against these mutant EGFR forms (Supplementary Figure S3A). None of the TKIs was effective against the exon 20 insertion mutation (Supplementary Figure S3B). For the EGFRvIII mutant, AZD9291 demonstrated lower potency compared to afatinib and AZD8931. AZ5104, however, displayed a higher level of activity (Supplementary Figure S3C). These data are consistent with the kinase activity of the vIII mutant being similar to that of their wild-type EGFR.

We similarly explored activity against HER2 mutations found in NSCLC. Compared to afatinib and AZ5104, AZD9291 exhibited moderate potency against H1781 cells, which harbor a VC insertion at G776 in exon 20 of HER2 (42), with an IC50 of 80 nM (Supplementary Fig. S4A). However, AZD9291 was more effective at inhibiting growth of these cells than erlotinib. The effect of various TKIs on HER2-associated signaling in H1781 cells was consistent with these results (Supplementary Fig. S4B). Similar activity was observed in 293 cell transfectants harboring the most common HER2 mutant in NSCLC (exon20 YVMA 776-779ins) (43) (Supplementary Fig. S4C). Thus, in patients, AZD9291 and its metabolite AZ5104, may also be able to target HER2 in tumors, depending on the clinical exposures that are achieved.

**AZD9291 causes profound and sustained regression in mutant EGFR in vivo xenograft models**
AZD9291 demonstrated good bioavailability, was widely distributed in tissues, and had moderate clearance resulting in a half-life of around 3 hours after oral dosing in the mouse (Supplementary Fig. S5). The circulating active metabolites in plasma each had a similar half-life, and the total exposure levels (AUC) were approximately 68 and 33% compared to the parent compound for AZ7550 and AZ5104, respectively (Supplementary Fig S5).

To explore in vivo activity of AZD9291, we administered the drug as monotherapy against various mutant EGFR xenografts representing clinical NSCLC settings. Once daily dosing of AZD9291 induced significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models, with tumor shrinkage observed at doses as low as 2.5mg/kg/day in both models after 14 days (Fig. 4A, B). Similar tumor shrinkage was seen after administration of 5 mg/kg/day AZD9291 in H3255 (L858R) (Supplementary Fig. S6A) and PC-9VanR (ex19 del/ T790M) (Supplementary Fig. S6B) xenografts after 14 days. These studies showed that AZD9291 can induce profound shrinkage at low doses against both EGFR drug-sensitizing and T790M-resistant EGFR mutant disease models.

We next explored the durability of tumor shrinkage. Chronic long term daily oral dosing of AZD9291 resulted in complete and durable macroscopic responses of both PC-9 (Fig. 4C) and H1975 xenografts (Fig. 4D). For PC-9 cells, no visible tumors were evident following 40 daily doses with 5 mg/kg of AZD9291 in 8 of 8 tumors, and this complete response was sustained out to 200 days when the study was terminated (data not shown). As a comparison, gefitinib at 6.25 mg/kg/day, a clinically representative dose, induced less tumor regression, and tumors began to re-grow after approximately
90 days. In H1975 xenografts, 5 mg/kg/day AZD9291 resulted in complete responses in 10 of 12 tumors. Re-growth was observed after approximately 50 days treatment with 1 mg/kg/day, but an increased dose of 25 mg/kg/day AZD9291 re-induced tumor regression possibly suggesting re-growth was still driven by T790M EGFR. No visible tumors were evident after 20 days dosing of 25 mg/kg/day AZD9291 in the H1975 xenograft model. Moreover, the complete responses were maintained for the duration of the study period with no evidence of tumor progression during 200 days of treatment. No growth was observed for an additional 30 days after treatment was stopped. AZD9291 daily dosing was well tolerated in the animals with minimal body weight loss, (less than 5% of starting body weight) even after dosing for 200 days (Supplementary Fig. S6C (PC-9) and S6D (H1975)). Similar long term dosing studies were performed in the H3255 model, with 5 mg/kg/day AZD9291 causing non-measurable tumors in all 8 dosed mice by day 53. By contrast, only one mouse treated with 6.25 mg/kg gefitinib achieved non-measurable tumor status (Supplementary Fig. S6A).

To explore comparative efficacy against wild-type EGFR, AZD9291 was tested in A431 xenografts. These cells are used as a model for wild-type EGFR activity, but they are highly dependent on amplified wild-type EGFR and therefore are unlikely to reflect normal tissue EGFR pharmacology/physiology (44). AZD9291 did induce some moderate tumor growth inhibition at 5 mg/kg/day (Supplementary Fig. S6E), suggesting AZD9291 or associated metabolites are not entirely inactive against wild-type EGFR in this model. By contrast, this same 5 mg/kg/day dose level was sufficient to induce profound and sustained tumor shrinkage in both H1975 and PC-9 mutant
EGFR tumor xenograft models (Figs. 4A-B), consistent with AZD9291 having a significant selectivity margin over wild-type EGFR.

AZD9291 causes profound and sustained regression in mutant EGFR in vivo transgenic tumor models

We further examined tumor responses in previously generated mouse tumor models that develop lung adenocarcinomas driven by EGFR\textsuperscript{L858R} (45) or EGFR\textsuperscript{L858R + T790M} (46). These models employ a tetracycline–inducible (tet-inducible) system, involving bitransgenic animals. One transgene carries a tet transactivator in lung epithelia (i.e., Clara cell secretory protein – reverse tetracycline transactivator [CCSP-rTA], herein referred to as “C” mice). The 2 relevant strains are referred to as C/L858R and C/L+T, respectively. As expected, tumors harboring EGFR\textsuperscript{L858R} were sensitive to erlotinib, while tumors expressing EGFR\textsuperscript{L858R + T790M} were resistant (46). Here, we treated tumor-bearing mice with AZD9291 (5 mg/kg/day), afatinib (7.5 mg/kg/day), or vehicle control for one to two weeks. Within days of treatment, 5 of 5 C/L858R mice displayed nearly 80% reduction in tumor volume by magnetic resonance imaging MRI (see Methods and (47)) after therapy with both afatinib or AZD9291, while 5 of 5 mice treated with vehicle showed tumor growth (Figs. 5A (top) and 5B). Upon histological examination, only vehicle-treated mice showed viable tumor (Fig. 5B). By contrast, in C/L+T animals, only AZD9291 treatment induced significant tumor shrinkage (Figs. 5A (middle&bottom) and 5C), while both vehicle- and afatinib-treated mice showed viable tumor (Fig. 5C). The difference in tumor responses was more pronounced after 2 weeks of treatment (Fig. 5A (bottom)). Furthermore, preliminary data in a single mouse
with tumor driven by an ex19del mutant alone (45) also responded rapidly to AZD9291 (Supplementary Fig. S7A). The metabolite, AZ5104 (5 mg/kg/day), was also effective in shrinking tumors in both C/L858R (Supplementary Fig. S7B, C) and C/L+T mice (Supplementary Fig. S7B, D).

**Pharmacodynamic confirmation of target inhibition by AZD9291**

To confirm on-target and pathway activity of AZD9291, we examined tumor tissues from the H1975 xenograft and L858R/T790M transgenic model after drug treatment. Mice bearing H1975 xenografts were given a single dose of AZD9291 (5 mg/kg) and tumors were harvested 1, 6, 16, 24, and 30 hours later. Sections from formalin-fixed paraffin-embedded tumors were then stained for the phosphorylated forms of-EGFR (Tyr1173), ERK (Thr202/Tyr204), S6 (Ser235/236), and PRAS40 (Thr246). In the H1975 model, AZD9291 treatment strongly inhibited both phospho-EGFR and downstream signalling pathways after 6 hours (Fig. 6A). Although in mice, the pharmacokinetic half-life of AZD9291 is only ~3 hours, phospho-EGFR staining remained significantly diminished even after the 30 hour time point, consistent with its expected irreversible mode of action. Interestingly, although downstream signaling molecules similarly showed maximal inhibition after 6 hours, in contrast to phospho-EGFR, they displayed more transient inhibition (Fig. 6A).

In the transgenic model, we similarly observed target inhibition after 5mg/kg dosing of AZD9291 via immunohistochemical staining of sections for phospho-EGFR and downstream markers (Fig. 6B) or immunoblotting of lysates (Fig. 6C) from treated tumors.
Proof of principle clinical activity of AZD9291 in patients with acquired resistance to EGFR TKIs

The mesylate salt of AZD9291 is currently in a first-in-human phase I dose escalation clinical trial (AURA; NCT01802632; AstraZeneca) in patients with advanced EGFRm+ NSCLC who had disease progression following treatment with any EGFR TKI (including gefitinib or erlotinib). As proof-of-principle, here we present preliminary results of the first two patients in the study with confirmed radiographic responses (as per RECIST 1.1 (48) treated at the lowest dose cohort (20 mg once daily) (Fig. 7) (49). Both patients’ tumors harbored drug sensitive EGFR mutations in addition to documented T790M mutations (according to local testing results). Consistent with AZD9291 being less active against wild-type EGFR, in these two cases there were no rash events and only one reported CTCAE Grade 1 diarrhea. Preliminary clinical pharmacokinetic analysis indicates that AZD9291, AZ5104 and AZ7550 have a half-life of at least 50 hours, longer than would be predicted from the preclinical data, which results in a desirable flat PK profile after multiple once daily dosing (Fig 7A). Further Phase 1 clinical data for this study will be submitted for publication at a later date.

The first patient was a 57-year old East Asian female patient from South Korea diagnosed with Stage IV EGFR mutant (ex 19 del) NSCLC in May 2011. The patient had disease progression following 2 cycles of gemcitabine plus carboplatin combination chemotherapy. The patient next had a partial response on gefitinib before developing disease progression after 10 months. She then had stable disease with 4 cycles of pemetrexed followed by 4 cycles of paclitaxel plus carboplatin with a best response of
partial response before progressing immediately before study. Analysis of tumor tissue, from a biopsy taken immediately before AZD9291 study entry, using direct dideoxynucleotide-based sequencing, revealed presence of a T790M mutation (data not shown). Tumor shrinkage on AZD9291 was 39.7% at scan 1, 48.3% by scan 2 (Fig. 7B), remained at 48.3% at both scan 3 and scan 4, and was 51.7% at scan 5 (data not shown).

The second patient was a 57-year old white female never smoker from England diagnosed with Stage IV lung adenocarcinoma in December 2010. Analysis of tumor tissue obtained at diagnosis in a local molecular pathology lab using the Qiagen EGFR RGQ PCR test revealed evidence of exon 19 deletion and T790M mutations (data not shown). The patient was treated with first-line gefitinib, achieving a partial response before eventual progressive disease 14 months later, suggesting that the T790M mutation was present at only a low allele frequency. Re-biopsy prior to starting AZD9291 was not performed. At the cycle 1 day 15 assessments on AZD9291, the patient reported full resolution of pre-existing persistent nocturnal cough. Tumor shrinkage was 38% at scan 1, 39.3% at scan 2, 56.7% by scan 3 (Fig. 7C), 62% by scan 4, and 59.3% by scan 5 (data not shown). By Cycle 7 Day 1, the patient reported significant improvement in pre-existing hair and eyelash abnormalities which had developed during the immediately prior gefitinib therapy. Since this patient received AZD9291 after developing acquired resistance whilst on continuous gefitinib (after initial > 6 months duration of partial response) with no intervening treatment, strict Jackman clinical criteria for acquired resistance were fulfilled (50). No significant aberration of blood glucose levels were noted in either patient during the study. Both patients had a
duration of response of approximately 9 months and were progression-free on 20 mg/day AZD9291 for approximately 11 months, until disease progression by RECIST 1.1. Both patients continue to receive AZD9291 treatment on study as per protocol, as they continue to derive clinical benefit according to their treating physicians.

Discussion

Mutations in EGFR occur in 10-35% of NSCLCs and confer sensitivity to the EGFR TKIs erlotinib, gefitinib, and afatinib (6). In randomized studies, the median overall survival of patients with EGFR mutant lung cancer receiving first-line EGFR TKIs is ~19-36 months, while median progression free survival is about a year. In more than half of patients, tumor cells at the time of progression harbor a second-site T790M mutation, which confers resistance to these EGFR TKIs (23). No specific treatments for patients with acquired resistance to current EGFR TKIs have yet been approved.

We describe here the identification, characterization and early clinical development of AZD9291, a novel oral, irreversible, third generation TKI with a distinct profile from gefitinib, erlotinib, afatinib, and dacomitinib. Notably, AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (51). Biochemical profiling together with in vitro cellular phosphorylation and phenotype studies have collectively shown that AZD9291 is highly potent against EGFRm+ and T790M resistant EGFR mutants with a wide margin of selectivity against wild type EGFR activity and exhibits a high degree of selectivity against other kinases outside the EGFR family. Moreover, the profound anti-tumor activity of AZD9291
across xenograft and transgenic mutant T790M EGFR disease models \textit{in vivo} suggests the potential to target T790M tumors following progression on early generation TKIs.

Prior to identification of “third generation” EGFR TKIs, the most promising targeted regimen in patients with acquired resistance had been the combination of afatinib plus cetuximab, which induced a 32% response rate and median progression-free survival of 4.7 months in a heavily pre-treated cohort (52) with a significant degree of skin and gastrointestinal (diarrhea) toxicity. In the phase I trial of AZD9291 in EGFRm+ NSCLC patients that had progressed on earlier generation TKIs, evidence of efficacy has been seen at all doses studied so far, with AZD9291 induced partial radiographic responses in patients whose tumors were known to harbor T790M, from the first dose cohort onwards (49, 53). Rash and diarrhea were mostly mild and reported in only a minority of patients, consistent with low activity against wild-type EGFR. Out of the two confirmed partial responses described in this paper, in addition to both patients’ tumors harboring the T790M mutations (according to local tests), one patient’s disease fits strict Jackman criteria for acquired resistance (50), receiving the drug directly after prolonged response and progression on gefitinib. Thus, based on the above, AZD9291 has already demonstrated proof-of-principle clinical activity in patients with acquired resistance for whom there are no approved targeted therapies. Similarly, results from a phase I trial with CO-1686 have also shown evidence of efficacy in TKI-resistant tumors harboring T790M (54) (55), providing further proof of principle for potential use of “third generation” TKIs in this setting. A surprising finding in the afatinib plus cetuximab study was that tumors with undetectable levels of T790M also displayed tumor shrinkage, suggesting that a T790M-independent but EGFR-dependent pathway...
of resistance exists. The current phase I study of AZD9291 will test whether the drug is effective in both T790M-positive and –negative cohorts, through planned dose-expansion cohorts. Full Phase I data will be presented at completion of study.

The existence of cell populations harboring T790M within a proportion of TKI-naïve EGFRm+ tumors has been reported, although the prevalence depends on the diagnostic assay being used. Studies using more conventional diagnostic assays have reported detection in about 2% of TKI-naïve tumors (56). Recently, groups using more sensitive technologies have reported higher detection rates ranging from 40% to 60% (57), although it remains unclear whether all these observations are real or analytical artifacts (58). However, overall the data supports the hypothesis that T790M clones pre-exist in a proportion of EGFRm+ tumors prior to TKI treatment. In addition to T790M, AZD9291 also potently inhibits sensitizing mutant EGFR across in vitro and in vivo disease models at similar potencies to T790M-mutant EGFR. Therefore, taken together, this supports the hypothesis that AZD9291 could also offer an attractive treatment option in EGFRm+ TKI-naïve patients, through targeting both sensitizing and T790M tumour cell populations that co-exist in a proportion of tumors, which may then lead to delayed disease progression and ultimately increased survival benefit.

However, it remains to be determined what the optimal sequencing of EGFR TKIs will be and whether maximum benefit to most patients will be achieved through using AZD9291 after TKI progression or earlier in the treatment pathway.

Patients harboring EGFRm+ tumors often progress during TKI treatment due to growth of secondary brain metastases (BM) (59). Although there are reports of TKIs providing benefit in treatment of EGFRm+ BM, current TKIs are believed to have
generally poor properties for penetrating across the blood brain barrier (BBB), and thus their activity will be variable and influenced by such factors as dose, level of BBB disruption and efflux transporter expression across individuals. Therefore, there is also a need for EGFR TKIs with improved brain penetrance. Quantitative whole body autoradiography (QWBA) studies in rat brain with $[^{14}\text{C}]\text{AZD9291}$ have indicated AZD9291 had a brain-to-blood ratio of up to 2 over the first 24 hours, suggesting the potential of AZD9291 to penetrate the brain (data not shown). This is in contrast to $[^{14}\text{C}]\text{gefitinib}$ which had a maximum brain-to-blood ratio of only 0.2 (60). Although further pre-clinical studies are required to explore the translatable potential of AZD9291 to target brain metastases, together with future clinical studies, the preliminary data look promising in this area.

Despite the potential of AZD9291 to prevent resistance via T790M, tumors are likely to engage alternative escape mechanisms. If TKIs such as AZD9291 become a prominent feature in the treatment of EGFRm+ disease across multiple lines of therapy, it will be critical for future pre-clinical and clinical research to identify the most prevalent future resistance mechanisms. Consistent with its pharmacological profile, we have not observed acquired resistance to AZD9291 in vitro due to emergence of T790M. It is also interesting to note that we not yet seen resistance to AZD9291 due to direct mutation of cysteine 797 (data not shown), which would render the receptor refractory to irreversible agents, in an analogous manner T790M prevents inhibition by early generation drugs. Therefore, non-EGFR related resistance mechanisms may become more dominant for agents such as AZD9291. Indeed, pre-clinical reports have suggested that “third generation” agents can induce switching to multiple signaling
mechanisms that bypass EGFR dependency such as ERK and AKT pathways (35, 61, 62). Since AZD9291 is structurally distinct, it will be critical to understand which resistance mechanisms are induced through treatment with AZD9291 and whether different “third generation” TKIs engage common escape mechanisms. Furthermore, identification of molecular mechanisms of resistance will support the investigation of strategies to combine additional novel targeted therapies with AZD9291 as a foundation EGFR TKI partner, to achieve potentially greater clinical benefit.

AZD9291 and its active circulating metabolite AZ5104 display similar and minimal off-target activity against other non-HER family kinases, but in vitro data suggests the potential to target both HER2 and HER4 kinase activity. This property may be important as HER2 amplification may mediate acquired resistance to EGFR TKI in some cases (13). AZD9291 and AZ5104 also appear to be effective against other rare drug-sensitive EGFR mutants and potentially lung cancer-associated HER2 mutants, but like other EGFR TKIs are not potent against an EGFR exon 20 insertion. Further pre-clinical and clinical studies are required to understand the potential utility of AZD9291 in these additional molecular phenotypes.

Earlier generation EGFR TKIs have revolutionized the treatment of EGFRm+ NSCLC and have demonstrated the power of precision medicine in genetically-defined tumors. However, toxicities related to wild-type EGFR and the emergence of resistance mechanisms have limited the effectiveness of these drugs. Third generation EGFR TKI agents such as AZD9291 have the potential to overcome these limitations and improve markedly the treatment options to patients who have progressed on TKI treatment due to T790M. Evaluation of AZD9291 in the 1st line setting in patients with EGFRm+
tumors should also be considered based on AZD9291’s third generation EGFR TKI profile. Moreover, if AZD9291 is confirmed to have a mild side effect profile together with its clinical efficacy and mechanistic hypothesis, this raises the option for investigation as a foundation EGFR TKI for combinations with other therapies to provide further treatment options for patients.

**Acknowledgements**

We thank the wider AstraZeneca AZD9291 project team for supporting the pre-clinical identification and development of AZD9291. Specifically we acknowledge Anne Galer and Paula Daunt for pre-clinical and clinical project team leadership. Kathryn Brown, Rik Dattani and Joanne Wilson for assistance with DMPK studies and Scott Martin for contribution to identification of the metabolites. Mark Anderton for leading pre-clinical toxicology studies. Thanks to David Smith, Keith Welsh, Helen Musgrove, Vicky Sheridan, Emily Lawrie and Paula Taylor for expert technical support and to Peter Hall for pathology input. We acknowledge support from Gayle Marshall, Claire Barnes, Lucy O’Brien and Laura Ratcliffe for assistance in generating some of the resistance models and Malcom Anderson for studying AZD9291 binding to recombinant protein. At Vanderbilt, we thank Helen Pan for assistance with molecular genotyping assays and Daniel Colvin and Fuxue Xin for magnetic resonance imaging assistance.

**Contributions**

D.C., lead of the AstraZeneca scientific team, designed the study programme, analysed and interpreted the data. S.A., C.N., E.I., C.E., P. B., K. A-K., P.S., G.H., V.J.,
M.M, M.R.B., R. R., J.S, H.J, J.O, A.R., designed, performed, analysed and interpreted data from specific experiments. R.W. and M.R.V.F, medicinal and computational chemists responsible for discovery of AZD9291, provided, analysed and interpreted data. S.G, M.C., M.R., D.W.K. designed the clinical study, provided, analysed and interpreted data. T.K. and G.R. led the discovery phase of the AZ study programme design, concept, and interpretation of the data. W.P., lead of the Vanderbilt scientific team, designed experiments, analysed and interpreted the data. D.C. and W.P. wrote the manuscript. All authors reviewed and input to the manuscript drafts and approved the final manuscript for submission.
Materials and Methods

Modelling the binding mode of AZD9291

A published structure of the EGFR T790M mutant (pdb code 3IKA (34)) was used for the modelling of potential binding modes of AZD9291. Crystal structures were prepared using the protein preparation wizard in Maestro (Schrödinger Release 2013-1) which optimises hydrogen placements. The active site was defined by using the bound ligand, and the covalent docking protocol was used to model potential binding modes. These were ranked using the assigned scores and manually inspected for the retention of the key hinge interactions to the hinge region residue M793.

Cell lines. All AZ cell lines were tested and authenticated by short-tandem repeat analysis (STR). PC-9 cells were obtained in Nov 2011 from Akiko Hiraide at Preclinical Sciences R&D AZ Japan and last STR tested in May 2013. NCI-H1975 (H1975; CRL-5908. Obtained 2004 and last STR tested Nov 2012), Calu-3 (HTB-55. Obtained 2010 and last STR tested June 2013), NCI-H1650 (H1650; CRL-5883. Obtained 2004 and last STR tested Sept 2011) and NCI-H2073 (H2073; CRL-5918. Obtained 2007 and last STR tested Nov 2012) cells were obtained from ATCC. LoVo cell line (CCL-229) was obtained from ECACC in 1995 and last STR tested Jan 2013. PC-9 Vandetinib resistant cells (PC-9VanR) were obtained in 2010 from Dr. Kiura at Okayama University and last STR tested Sept 2011. A431 cell line was obtained in 2004 from Prof Mike Waterfield at ICRF London and STR tested May 2012. All other cell lines were available in the Pao lab and have been used as reagents in the Pao Lab since 2005.
Pao lab cell lines were re-genotyped multiple times to confirm the presence of known EGFR mutations by standard Sanger sequencing to ensure the accuracy of experiments. Cells were cultured in standard RPMI media (Corning) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals), 2mM L-glutamine (Corning) and 1% penicillin/streptomycin (Corning) and grown in a humidified incubator with 5% CO₂ at 37°C. Resistant cells were maintained under constant TKI selection prior to use in experiments.

**In vitro EGFR phosphorylation assays.** Cells were treated for 2 h with a dose-response of each drug. Wild-type cells were stimulated for 10 minutes with 25 ng/ml of EGF before lysis. Level of EGFR phosphorylation was quantified in cell extracts using a modified R&D Systems DuoSet Human phospho-EGFR ELISA (36).

**In vitro cell phenotype assays.** Cellular Sytox proliferation assays were performed as described (36) and Origin software used to interpolate IC₅₀ values. Growth inhibition assays were performed using CellTiter Blue Reagent (Promega, G8081) as described, (13) and IC₅₀ values were calculated using Excel (Microsoft).

**Generation of EGFR inhibitor resistant cell populations**

PC-9 cells were seeded into T75 flasks (5 x 10⁵ cells / flask) in RPMI growth media and incubated at 37°C, 5% CO₂. The following day the media was replaced with media supplemented with a concentration of EGFR inhibitor equal to the EC₅₀ concentration predetermined in PC-9 cells. Media changes were carried out every 2-3 days and
resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised
and reseeded at the original seeding density in media containing twice the
concentration of EGFR inhibitor. Dose escalations were continued until a final
concentration of 1.5μM gefitinib, 1.5μM afatinib, 1.5μM WZ4002 or 160nM AZD9291
were achieved.

**Expression vectors and transfections.** The indicated EGFR cDNAs were cloned into
the pcDNA3.1(−) expression vector and altered using site-directed mutagenesis as
described (5). All cDNAs were re-sequenced to verify that no additional codon-changing
mutations were present. pCDH-puro-EGFRvIII lacking exons 2-7 in EGFR (a kind gift
from Dr. Jialiang Wang, Vanderbilt University) was constructed by subcloning the
EGFRvIII fragment from MSCV-XZ066-EGFRvIII (Addgene Plasmid# 20737
[http://www.addgene.org/20737/](http://www.addgene.org/20737/)) into the expression vector pCDH-CMV-MCS-EF1-
Puro. pBabe-HER2YVMA-puro (a kind gift from Carlos Arteaga, Vanderbilt University)
encodes HER2 with an in-frame YVMA insertion at residue 776 (43). All plasmids were
transfected into 293 cells as described (5).

**Immunoblotting.** Cells were washed on ice with cold PBS before addition of
radioimmunoprecipitation assay (RIPA) buffer (150 mmol/L Tris-HCl, pH 7.5, 150
mmol/L NaCl, 1% NP-40 substitute, 0.1% SDS) supplemented with protease inhibitor
cocktail (Roche), 40mmol/L sodium fluoride, 1 mmol/L sodium orthovanadate, and 1
μmol/L okadaic acid. After scraping, lysates were transferred to microcentrifuge tubes
and shaken at 4°C for 20 minutes before 10 minute centrifugation and protein
quantification with Bradford Reagent (Bio-Rad). Equal protein amounts were loaded for SDS-PAGE using 4-12% gradient or 10% Bis-Tris precast gels (Novex Life Technologies), followed by transfer to polyvinylidene difluoride membranes using the iBlot dry transfer system (Novex Life Technologies). After blocking in 5% BSA-TBST or milk-TBST, membranes were blotted with total EGFR (BD Biosciences, #610017), phospho-EGFR (Tyr1068, R&D Systems, MAB3570 or Tyr1173, Santa Cruz Technologies, Inc, sc-12351), total AKT (Cell Signaling, 9272S), phospho-AKT (Ser473, Cell Signaling, 9271L), total ERK (Cell Signaling, 9102L), phospho-ERK (Thr202/Tyr204, Cell Signaling, 9101L), prosurfactant protein C (Abcam, ab90716) or actin (Sigma, A2066) followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling, 7074 or 7076). Signals were detected with Western Lightening Plus detection reagents (Perkin Elmer, NEL10500NEA).

**Molecular genotyping.** AZD9291 resistant cells were assessed for EGFR T790M and other recurrent lung-associated mutations using an established assay (63).

**Xenograft studies.** All studies involving animals in the UK were conducted in accordance with UK Home Office legislation, the Animal Scientific Procedures Act 1986 (ASPA) and with Astrazeneca Global Bioethics policy. All experimental work is outlined in project licence 40/3483 which has gone through the AstraZeneca Ethical Review Process. NCI-H1975 and A431 cells for in vivo implant were cultured in DMEM (Invitrogen) supplemented with 10% v/v fetal calf serum (Sigma Aldrich) and 1% v/v L-
glutamine (Invitrogen). PC-9 cells were cultured in RPMI 1640 (Invitrogen) supplemented with 10% v/v fetal calf serum, 1% v/v L-glutamine and 10% v/v M1 supplement (Egg Technologies). All cell lines were then cultured in a humidified incubator with 7.5% CO₂ at 37°C. Cells were detached using 0.05% trypsin (Invitrogen) and re-suspended for implant in serum-free media. 5 x 10⁶ cells were implanted subcutaneously in a total volume of 0.1ml/mouse for PC-9 and NCI-H1975, and 1 x 10⁷ cells implanted subcutaneously for A431. Both PC-9 and A431 cells were implanted in 50% matrigel. PC-9 xenografts were established in female scid mice and NCI-H1975 and A431 were established in female nude mice. All mice were greater than 6 weeks old at time of cell implant. Tumor growth was monitored twice weekly by bilateral caliper measurements, tumor volume calculated, and mice randomized into vehicle or treatment groups with approximate mean start size of 0.2-0.4cm³. Randomisation for animal studies is based on initial tumor volumes to ensure equal distribution across groups. A power analysis is performed whereby group sizes are calculated to enable statistically robust detection of tumor growth inhibition. Mice were dosed once daily by oral gavage for duration of the treatment period. Tumor growth inhibition from start of treatment was assessed by comparison of the mean change in tumor volume for the control and treated groups. Statistical significance was evaluated using a one-tailed Students t test.

For pharmacodynamic studies, mice were randomized at a mean tumor volume of approximately 0.5-0.8cm³ using the same randomization criteria as the tumor growth inhibition studies. Mice were then treated orally with a single bolus dose of either vehicle or AZD9291. Tumors were excised at specific timepoints after dosing and fixed in 10%
buffered formalin. Immunohistochemical analysis was performed on formalin fixed, paraffin embedded tissue sections staining for phosphorylated EGFR (Tyr1173) and phosphorylated ERK (p44/42 Thr202/Tyr204).

**Transgenic Mouse Studies.** All animals were kept in pathogen-free housing under guidelines approved by the Vanderbilt University Medical Center Institutional Animal Care and Use Committee. The generation of EGFR<sup>L858R</sup> (45) and EGFR<sup>L858R+T790M</sup> mice (male and female) was previously described (46) Doxycycline was administered by feeding mice (approx 3 week old) with doxycycline-impregnated food pellets (625 ppm; Harlan-Teklad), and treated for about 3 months during which time tumors developed. Afatinib and AZD9291 were suspended in 1% Polysorbate 80 and administered via oral gavage once daily at the doses of 7.5 mg/kg and 5 mg/kg, respectively. Mice were imaged weekly at the Vanderbilt University Institute of Imaging Science. For immunoblot analysis, mice were treated for eight hours with drug as described before dissection and flash freezing of the lungs. Lungs were pulverized in liquid nitrogen before lysis as described above.

**MRI.** All procedures were approved by Vanderbilt’s Institutional Animal Care and Usage Committee. Mice were anesthetized via inhalation of 2%/98% isoflurane/oxygen and maintained under anesthesia throughout the course of the experiment. Animals were secured in a prone position in a 38-mm inner diameter radiofrequency (RF) coil and placed in a Varian 7T horizontal bore imaging system (Varian Inc, Palo Alto, CA) for
data collection. A constant body temperature of 37°C was maintained using heated air flow. Prior to treatment, mice were scanned at least twice to confirm the presence of growing lung nodules and to avoid treating false-positive animals.

Multi-slice T1-weighted gradient echo images were collected in all three imaging planes (axial, sagittal, and coronal) for localization of the lungs (repetition time (TR) = 100ms, echo time (TE) = 5ms, slice thickness = 1mm, 40mm x 40mm field of view (FOV), approximately 15-20 slices). Following the initial scout imaging, respiratory triggered, segmented fast low angle shot (FLASH) images were collected in both the axial and coronal planes with TR/TE = 850/2.8ms, flip angle = 15 degrees, number of slices = 22, slice thickness = 0.7mm with a 0.2mm gap between slices, and number of acquisitions = 16. For the axial images, the FOV = 23.04mm x 23.04mm, with a matrix size of 256x256, resulting in an in-plane resolution of 90 microns. For the coronal orientation, FOV = 30.72mm x 23.04mm, with a data matrix = 256x256, resulting in an in-plane resolution of 120x90 microns.

Following image acquisition, lung tumor volume measurements were performed using Matlab 2012a (The MathWorks, Inc, Natick, MA). A region of interest (ROI) was manually drawn around the lungs for each slice, excluding the heart, and a signal intensity threshold of 25 times the noise level (defined as the standard deviation of signal intensities in a region of the image background) was used to segment voxels within that ROI as positive for tumor. Total lung tumor volume was then calculated by multiplying the tumor area within the segmented region by 0.09 cm (the distance between each MRI slice).
**Immunohistochemistry**

4um sections were deparaffinized with xylene and rehydrated through graded alcohols into water. Antigen retrieval was carried out in a Milestone RHS microwave rapid histoprocessor for 10 minutes at 110°C in pH9 buffer, Dako S2367 (for phospho-EGFR and phospho-Akt) and pH 6 citrate buffer, Dako S1699 (for phospho-Erk and phospho-S6). Tissues were placed on a LabVision Autostainer, endogenous peroxidase was blocked with 3% H₂O₂ for 10 minutes, followed by washing twice in TBS/0.05% Tween. Serum free protein block (Dako; X0909) was applied for 15 minutes. Slides were then incubated with the primary antibodies at room temperature, phospho-EGFR Tyr1173 (Cell Signaling Technology, code 4407) at a 1:200 dilution, phospho-ERK (p44/42 Thr202/Tyr204) (Cell Signaling Technology, code 4376) at 1:100, phospho-S6 (Ser 235/236) CST #4857 at 1:150, phospho-PRAS40 (pThr246) (Cell Signaling Technology, code #2997) at 1:200, and phospho-Akt308 CST #2965 at 1:100 dilution. After washing twice, sections were incubated for 30 minutes with Rabbit Envision polymer detection system (Dako K4003), washed twice and then developed in liquid 3,3-_diaminobenzidine (DAB) for 10 minutes. Sections were then counter-stained with Mayer’s haematoxylin, dehydrated, cleared, and mounted with coverslips.

**Patients.** All patients were treated on trial NCT01802632 with written informed consent from patients and approval appropriate Institutional Review Boards (For the two patients disclosed in this manuscript the Ethics committees are as follows; Korean patient: Seoul National University Hospital (EC), UK patient: North West – GM Central, North West Centre of REC, Manchester). Consent to publish study CT scan images is included as
part of the patient informed consent, signed by both patients. In the first into man study a cohort size of 6 for the starting dose is standard practice, to provide sufficient safety and tolerability data about a dose level without exposing too many patients to a dose which may not be clinically beneficial. The first two patients in the starting dose cohort with an objective response were selected for inclusion in the publication. The clinical study is ongoing and further study data will be submitted for publication at a later date.

**Patient tumor genotyping in the trial.** Patient tumor tissues were analyzed for EGFR mutations using either the Qiagen EGFR RGQ PCR Kit [Cat #870111] or direct dideoxynucleotide sequencing.
Literature Cited


Figure Legends

Figure 1. AZD9291 binding mode and structure. A, Structural model showing the covalent mode of binding of AZD9291 to EGFR T790M via Cys-797. Shows pyrimidine core forming two hydrogen bonds to the hinge region (Met-793), orientation of the indole group adjacent to the gatekeeper residue, the amine moiety positioned in the solvent channel and the covalent bond formed to Cys-797 via the acrylamide group of AZD9291. B, Chemical structure of AZD9291.

Figure 2. Effect of AZD9291 on EGFR phosphorylation in vitro. A, In comparison to early generation TKIs, AZD9291 inhibits EGFR phosphorylation across cell lines harboring sensitising (PC-9, H3255, H1650) or T790M resistance (H1975, PC-9VanR) mutations, whilst having less activity against wild-type EGFR phosphorylation (LOVO, A431, H2073). Apparent geomean IC$_{50}$ (nM) values quantified in cell extracts after 2 h compound treatment using a phospho-EGFR ELISA from at least two separate experiments (expressed with 95% confidence intervals where n>3, or individual IC$_{50}$ values where n=2). B, AZD9291 inhibits EGFR phosphorylation and downstream signaling pathways across representative mutant EGFR lines (PC-9, H1975, H1650, H3255), whilst having less activity against EGFR phosphorylation in the LOVO wild-type EGFR cell line compared to early generation TKIs, after 6 h treatment. The data is representative of at least two separate experiments.

Figure 3. Additional characteristics of AZD9291 in vitro. A, AZD9291 demonstrates greater inhibition of viability against mutant EGFR cell lines compared to wild-type, as
assessed using a Sytox Green live/dead assay measured after 3 days treatment. The data represents the geometric mean IC$_{50}$ nM value from at least two separate experiments (expressed with 95% confidence intervals where n>3). B, Sensitivity of isogenic pairs of EGFR mutant drug-sensitive and –resistant lung cancer cell lines (PC-9, ex19del; PC-9/BRc1, ex19del/T790M; HCC827, ex19del; HCC827/ER1, ex19del/T790M; HCC827/ER2, ex19del/METamplification; H1650, ex19del/PTEN loss; HCC4006, ex19del; HCC4006/ER, EMT (epithelial mesenchymal transition); H3255, L858R; H3255/XLR, L858R/T790M; H1975, L858R/T790M; 11-18, L858R; 11-18/ER, L858R/NRAS) to AZD9291, erlotinib, and afatinib. IC$_{50}$s (μM) were based on data obtained from growth inhibition assays. C, T790M mutation was detected in multiple independent populations of PC-9 cells with acquired resistance to gefitinib or afatinib, but not in populations resistant to AZD9291.

**Figure 4.** *In vivo* anti-tumor efficacy of AZD9291 in subcutaneous xenograft models of EGFR-TKI sensitising and T790M resistant lung cancer. A, PC-9 (ex19del) xenograft following 14 days of daily treatment (n=6 or 8 animals depending on treatment group). B, H1975 (L858R/T790M) xenograft following 14 days of daily treatment (n=6 or 8 animals depending on treatment group). C, PC-9 following chronic daily oral dosing of 5mg/kg AZD9291 (n=8) or 6.25 mg/kg gefitinib (n=11). D, H1975 following chronic daily oral dosing of 1, 5 or 25 mg/kg AZD9291 (n=10 or 12 animals depending on dose group). Data are plotted as mean standard error.
Figure 5. AZD9291 induces significant and sustained tumor regression in transgenic models of EGFR-TKI sensitising (C/L858R) and T790M resistant (C/L+T) lung cancer. 
A, Percent change in radiographic tumor volume from baseline by treatment for individual lung tumor-bearing C/L858R (top) and C/L+T (middle, bottom) animals with vehicle, afatinib (7.5 mg/kg/day), or AZD9291 (5 mg/kg/day). B and C, Representative MRI images and H&E staining (original magnification, ×40) of lungs from tumor-bearing animals (B, C/L858R and C, C/L+T) pre and post treatment with vehicle, afatinib, or AZD9291 for 1 week. H – heart; L – liver; arrow denotes tumor.

Figure 6. AZD9291 inhibits EGFR phosphorylation and downstream signalling in murine models of EGFR T790M resistant lung cancer. A, Subcutaneous H1975 (L858R/T790M) xenografts, treated with a single 5 mg/kg dose of AZD9291 for the indicated times, were examined for phospho-EGFR, -ERK, -S6, and -PRAS40 status by immunohistochemistry. Representative images were taken from scans at 20x magnification and then size adjusted to fill the screen. B, Lungs from representative transgenic mice treated with control, AZD9291, or afatinib were harvested 6 hours after dose administration. Formalin-fixed paraffin-embedded sections were stained with the indicated antibodies. Representative images were taken from Aperio scans at 100x magnification. C. Lungs were harvested from either untreated tumor-bearing transgenic mice (as confirmed by MRI) (control) or from tumor-bearing mice 8 hours after a single treatment with AZD9291 5 mg/kg. Corresponding lysates from individual animals were immunoblotted with the indicated antibodies. Anti-SP-C (surfactant
protein C) antibody was used as a surrogate marker for tumor burden, as tumors express the protein.

**Figure 7.** Proof of concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. **A,** Preliminary pharmacokinetic profile showing mean (+ SD) total plasma levels of AZD9291, AZ5104 and AZ7550 versus time from cohort of 6 advanced NSCLC patients. After a single dose of AZD9291 mesylate salt, followed by a 7 day washout and then 8 days of once daily 20 mg oral dosing in AURA Phase 1 study (NCT01802632). **B and C,** Serial computed tomography scans of the chest from patients before and after treatment with AZD9291 in a phase I trial. **B,** Images from a 57-year old Korean female patient diagnosed with Stage IV non-small cell lung cancer in May 2011. See main text for details. **C,** Images from a 57-year old British female never smoker diagnosed with Stage IV lung adenocarcinoma in December 2010. The patient was previously treated with first-line gefitinib for 14 months, achieving a partial response before eventually developing progressive disease. See main text for details.
Figure 1

A

B
Figure 2

A

<table>
<thead>
<tr>
<th>Drug</th>
<th>H1975 (L858R/T790M)</th>
<th>PC-9 VanR (ex19del/L858R)</th>
<th>PC-9 (ex19del)</th>
<th>H3255 (ex19del)</th>
<th>H1650 (ex19del)</th>
<th>LoVo (WT)</th>
<th>A431 (WT)</th>
<th>NCI-H2073 (WT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZD9291</td>
<td>15 (10, 20)</td>
<td>6 (3, 13)</td>
<td>17 (13, 22)</td>
<td>60, 49</td>
<td>14, 12</td>
<td>480 (320, 720)</td>
<td>2376, 1193</td>
<td>1865 (872, 3988)</td>
</tr>
<tr>
<td>Dacomitinib</td>
<td>40 (24, 65)</td>
<td>6 (2, 17)</td>
<td>0.7 (0.5, 1)</td>
<td>1.2, 1.3</td>
<td>0.04, 0.06</td>
<td>12 (8, 17)</td>
<td>51, 22</td>
<td>26 (7, 99)</td>
</tr>
<tr>
<td>Afatinib</td>
<td>22 (15, 31)</td>
<td>3 (2, 6)</td>
<td>0.6 (0.5, 0.8)</td>
<td>1, 0.8</td>
<td>0.6, 3</td>
<td>15 (10, 24)</td>
<td>27, 40</td>
<td>25 (5, 129)</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>3102 (1603, 6001)</td>
<td>741 (484, 1136)</td>
<td>7 (5, 11)</td>
<td>11, 12</td>
<td>16, 19</td>
<td>59 (42, 82)</td>
<td>60, 88</td>
<td>61 (34, 110)</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>6073 (3634, 10150)</td>
<td>1262 (588, 2711)</td>
<td>6 (4, 7)</td>
<td>8, 11</td>
<td>5, 8</td>
<td>91 (53, 156)</td>
<td>244, 260</td>
<td>108 (52, 223)</td>
</tr>
</tbody>
</table>

B

![Diagram showing EGFR phosphorylation in LoVo cells treated with gefitinib, AZD9291, and Afatinib.](image)
Figure 3

<table>
<thead>
<tr>
<th></th>
<th>H1975 (T790M/L858R)</th>
<th>PC-9 VanR (ex19del/T790M)</th>
<th>PC-9 (ex19del)</th>
<th>Calu 3 (WT)</th>
<th>NCI-H2073 (WT)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AZD9291</strong></td>
<td>11 (6.19)</td>
<td>40 (30.54)</td>
<td>8 (7.9)</td>
<td>650 (457,924)</td>
<td>461 (230,924)</td>
</tr>
<tr>
<td><strong>Dacomitinib</strong></td>
<td>335 (265,424)</td>
<td>531 (465,607)</td>
<td>0.4 (0.3, 1)</td>
<td>65 (37,116)</td>
<td>54 (ND)</td>
</tr>
<tr>
<td><strong>Afatinib</strong></td>
<td>483 (403,579)</td>
<td>679 (532,868)</td>
<td>0.8 (0.7, 0.9)</td>
<td>71 (35,144)</td>
<td>30 (9, 99)</td>
</tr>
<tr>
<td><strong>Gefitinib</strong></td>
<td>6962 (6304,7688)</td>
<td>4232 (1998,8965)</td>
<td>23 (20,25)</td>
<td>1933 (1299,2876)</td>
<td>200 (41,974)</td>
</tr>
<tr>
<td><strong>Erlotinib</strong></td>
<td>6165 (5392,7050)</td>
<td>5778 (4766,7029)</td>
<td>28 (22,36)</td>
<td>4101 (2732,6156)</td>
<td>692 (193,2478)</td>
</tr>
</tbody>
</table>

B

C

Percentage of total number of populations

- No T790M detected
- T790M detected

Ge: gefitinib, A: afatinib, AZ: AZD9291
Figure 4

A

Log tumour volume $cm^3$

PC-9

Days

- Vehicle
- AZD9291 10mg/kg QD
- AZD9291 5mg/kg QD
- AZD9291 2.5mg/kg QD
- AZD9291 1mg/kg QD
- AZD9291 0.5mg/kg QD
- AZD9291 0.25mg/kg QD

B

Log tumour volume $cm^3$

NCI-H1975

Days

- Vehicle only
- AZD9291 25mg/kg QD
- AZD9291 10mg/kg QD
- AZD9291 5mg/kg QD
- AZD9291 2.5mg/kg QD
- AZD9291 1mg/kg QD
- AZD9291 0.5mg/kg QD

C

Log tumour volume $cm^3$

PC-9

Days

- Vehicle
- Gefitinib 6.25mg/kg/day
- AZD9291 5mg/kg/day

D

Log tumour volume $cm^3$

NCI-H1975

Days

- AZD9291 1mg/kg/day
- AZD9291 25mg/kg/day
- All dosing stopped
Figure 7

A

![Graph showing changes over time with data points for AZD9291, AZ5104, and AZ7550.]

B

Pre | 6W | 12W

![Images of X-rays at different time points, labeled Pre, 6W, and 12W.]

C

Pre | 6W | 24W

![Images of X-rays at different time points, labeled Pre, 6W, and 24W.]

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer


Cancer Discovery  Published OnlineFirst June 3, 2014.

Updated version  Access the most recent version of this article at: doi:10.1158/2159-8290.CD-14-0337

Supplementary Material  Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2014/06/03/2159-8290.CD-14-0337.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.